5th Gene Therapy for Neurological Disorders 2023

Memo

Despite a challenging 2022 for Gene Therapy developers targeting the CNS, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community. The 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments, overcome delivery challenges, address translational bottlenecks, and create a bulletproof clinical development strategy, to propel the next wave of CNS gene therapies forward. This summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights. Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders. URLs:Tickets: https://go.evvnt.com/1797350-2?pid=5569 Brochure: https://go.evvnt.com/1797350-3?pid=5569  Date and Time: On Mon, 06 Nov 2023 09:00 - Thu, 09 Nov 2023 16:00 Venue details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States Prices:Drug Developer Pricing - Full Access Pass (2 Day Conference + Pre-Conference Workshop Day AND Post-Conference Delivery Day): USD 5195.00,Drug Developer Pricing - 2 Day Conference + Workshop Day OR Post Conference Delivery Day: USD 4097.00,Drug Developer Pricing - 2 Day Conference Only: USD 2999.00,Solution Provider Pricing - Full Access Pass (2 Day Conference + Pre-Conference Workshop Day AND Post-Conference Delivery Day): USD 6395.00,Solution Provider Pricing - 2 Day Conference + Workshop Day OR Post Conference Delivery Day: USD 5097.00,Solution Provider Pricing - 2 Day Conference Only: USD 3799.00 Speakers: Adam Shaywitz, Chief Medical Officer, Bridge Bioscience Corp, Alfica Sehgal Senior, Vice President and Head of Discovery and Translation Discovery, CAMP4 Therapeutics, Ambreen Sayed-Zahid, Scientist, Voyager Therapeutics, Amy Hicks, Associate Director, Entrada Therapeutics Inc., Anindya Sen, Executive Director, Prevail Therapeutics, Dorota Gruber, Assistant Chief, Pediatric Cardiogenomics, Cohen Children's Medical Center, Dunni Odumosu, Vice President, Global Regulatory Affairs and Sciences, Bridge Bioscience Corp, Edgar Rodriguez-Lebron, Chief Executive Officer and Co-Founder, Lacerta Therapeutics Inc., Eloise Hudry, Associate Director - Cell, Gene Therapy and Preclinical Safety, NIBR, Fergus Quigley, Director - Early Stage Device Development Leader, Takeda Pharmaceutical Co. Ltd., Francesco Lotti, Assistant Professor - Pathology and Cell Biology, Project ALS Therapeutics Core, Frederic Padilla, Director Gene and Cell Therapy Program, Focused Ultrasound Foundation, Gabriele Proetzel, Senior Director - Neuroscience External Research, Takeda Pharmaceutical Co. Ltd., Gregory Stewart, Consultant, Alcyone Life Sciences, Habib Baghirov, Scientific Lead, Roche, Jan Panteli Director, Upstream Process Development and CMC Program Lead, Ultragenyx Pharmaceutical Inc, Jonathan Foley, Scientific Director, ArgoBio Studio, Joseph Glorioso, Professor, University of Pittsburgh, Juan Li, Senior Scientist - Research and Central Nervous System, Spark Therapeutics, Julia Taravella, Executive Director, Rare Trait Hope Fund, Katherine Deng, Senior Principle Scientist, Abbvie, Karen Pignet Founder, Chairman and Chief Executive Officer, Lysogene, Leszek Lisowski, Unit Head Translational Vectorology Research Unit, University of Sydney, Mansuo Shannon, Chief Scientific Officer, Prevail Therapeutics, Manuel Mohr, Director and Head of Vector Engineering, Former Cellinfinity Bio Employee, Manuel Sanchez-Felix, Associate Director, Novartis AG, Mark Richardson, Director of Functional Neurosurgery, Harvard University, Matt Kelley, Senior Scientist, Pfizer, Mengying Zhang, Vector Engineering Scientist, Biogen, Michal Fortuna, National Health Policy and Biodistribution Scientist Lead, Allen Institute, Nick Todd, Assistant Professor, Brigham and Women's Hospital, Ornit Chiba-Falek, Professor and Div Chief, Co-Founder, CLAIRIgene, Pannie Trifillis, Vice President and Head of Global Scientific Affairs,GMA, PTC Therapeutics, Sanjay Chandriani, Director, Maze Therapeutics, Sarah Jacobo, Global Gene Therapy and Vectorology Lead, Takeda Pharmaceutical Co. Ltd., Shyam Ramachandran, Senior Group Head of Neurologic Diseases, Sanofi, Sourav Choudhury, Head of Lab, Sanofi, Stephen Chrzanowski, Child Neurology Resident at Boston Children's Hospital, Boston Children's Hospital, Susan Catalano, Chief Scientific Officer, Capsida Biotherapeutics, Torben Moos, Professor, Aalborg University